Form 4: Curis CEO Acquires Convertible Stock, Warrants

Curis Inc.'s President and CEO, James E. Dentzer, acquired Series B Convertible Preferred Stock and associated warrants, signaling increased insider ownership.

Summary

• James E. Dentzer, President & CEO of Curis Inc., acquired 100 shares of Series B Convertible Preferred Stock and associated warrants on March 17, 2026.
• Each share of Series B Preferred Stock automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026.
• The acquisition included Series A, B, and C Warrants, each granting the right to purchase 133,333 shares of Common Stock at an exercise price of $0.75 per share.
• The Series A Warrants became immediately exercisable on March 17, 2026, and expire on January 8, 2031.
• The Series C Warrants became immediately exercisable on March 17, 2026, and expire on July 8, 2027.
• The Series B Warrants became immediately exercisable on March 17, 2026, and their termination date is tied to the fifth patient dosing in the company's Phase 2 clinical trial of emavusertib in combination with a Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia.
• The Series B Warrants' exercise price is subject to a potential reset if the common stock closing sale price is below $0.75 on the Initial Termination Date, with a floor of 50% of the initial exercise price, and the termination date may be extended by 30 days.
• The total purchase price for the combined securities (one Series B Preferred Stock share and one each of Series A, B, and C Warrants, collectively a 'Security') was $1,000.00 per Security.
• Following this transaction, Mr. Dentzer beneficially owns 100 shares of Series B Preferred Stock and 133,333 shares for each of the Series A, B, and C Warrants.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the CEO's direct investment through convertible preferred stock and warrants indicates confidence in the company's future value and strategic direction.

Positives

• The President & CEO, James E. Dentzer, increased his direct beneficial ownership in Curis Inc. through the acquisition of convertible preferred stock and warrants.
• This insider purchase signals management's confidence in the company's future prospects and valuation.
• The acquisition provides Mr. Dentzer with significant potential future common stock ownership, totaling approximately 533,332 shares if all preferred stock converts and all warrants are exercised.

Risks

• The Series B Warrants' exercise price is subject to a potential reset if the company's common stock closing sale price is below $0.75 on the Initial Termination Date, potentially reducing the exercise price (not below 50% of initial).
• The termination date of the Series B Warrants is contingent on the progress of the Company's Phase 2 clinical trial of emavusertib, introducing a dependency on clinical development milestones.

Future Outlook

The filing indicates future progress related to the Company's Phase 2 clinical trial of emavusertib in combination with a Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia, as it serves as a trigger for the termination date of the Series B Warrants.

Industry Context

StockSavvy.ai notes that insider purchases, especially by a CEO, can be interpreted as a sign of confidence in the company's future prospects within the biotechnology sector, particularly given the ongoing clinical trial activities mentioned.

Comparison to Industry Standards

• This Form 4 filing reports a specific insider transaction and does not contain financial results or operational metrics that can be directly compared to industry standards or specific comparable companies/projects.

Related Party Transactions

• The acquisition of Series B Convertible Preferred Stock and associated warrants by James E. Dentzer, the President & CEO, from Curis Inc. constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator of management's belief in the company's future performance and value.
• The company benefits from the capital raised through the sale of these securities.

Next Steps

• Automatic conversion of Series B Convertible Preferred Stock into Common Stock on March 20, 2026.
• Potential exercise of Series A, B, and C Warrants by the reporting person.
• Progress of the Company's Phase 2 clinical trial of emavusertib, which will determine the termination date for Series B Warrants.

Key Dates

Recommendation

The acquisition of convertible preferred stock and warrants by the CEO is a positive signal of insider confidence. However, a Form 4 filing primarily reports a transaction and does not provide comprehensive financial results or strategic updates necessary for a definitive 'buy' or 'sell' recommendation. Investors should consider this alongside broader company fundamentals and market conditions.

Keywords

Curis Inc, CRIS, Insider Trading, Form 4, Convertible Preferred Stock, Warrants, CEO, Stock Acquisition, Biotechnology, Pharmaceuticals, Emavusertib